Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 78

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 78
---
 equity compensation plans as of December 31, 2024, is included on page 31 of this Proxy Statement.

Vote Required

The affirmative vote of a majority of shares present in person or represented by proxy at the meeting and entitled to vote is required for the adoption of our 2025 Plan.

Board Recommendation

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTEFORAPPROVAL OF THE CERVOMED INC. 2025 EQUITY INCENTIVE PLAN.

<div align='center'>41

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

Our Audit Committee is charged with the responsibility of reviewing and approving or ratifying all related person transactions in accordance with the Listing Rules of the Nasdaq Capital Market and other applicable law, rules and regulations and any related policies and procedures adopted by or on behalf of the Company and then in effect.

Since January 1, 2023, there have been no transactions to which we have been a party in which (i) the amount involved in the transaction is the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years and (ii) any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock had or will have a direct or indirect material interest, except as set forth below:

Executive and Director Compensation

The employment agreements and other compensation arrangements between the Company, on the one hand, and each of our executive officers and directors, on the other hand, are described above under the headings, “Executive Compensation” and “Director Compensation.”

Indemnification Agreements

Our certificate of incorporation, as amended, states that we will indemnify our directors and executive officers to the fullest extent permitted by Delaware law. In addition, we have entered into customary indemnification agreements with each of our executive officers and directors who serve as officers and directors of the Company.

Pre-Funded Warrant Amendment and Exercise

In connection with the closing of the Merger, the Company issued a pre-funded warrant to the Boger Trust to purchase an aggregate of 495,995 shares of common stock for a purchase price of $0.001 per share. Joshua S. Boger, Ph.D., the Chair of the Board, is the sole trustee of the Boger Trust. On February 26, 2024, the Company and the Boger Trust entered into an amendment